PMHNP Scope of Practice for Narcolepsy

If you’re a psychiatrist or PMHNP considering treating narcolepsy patients remotely, you’re navigating one of the most complex intersections in telehealth: controlled substance prescribing, sleep disorder diagnosis, and a regulatory landscape that’s still evolving in 2026.

Here’s what you actually need to know about prescribing stimulants, modafinil, and other narcolepsy medications via telemedicine — and where the legal landmines are hiding.

The Short Answer: Yes (For Now), But It Depends on Your State

As of February 2026, psychiatrists and PMHNPs can prescribe narcolepsy medications — including Schedule II stimulants like Adderall and methylphenidate — via telehealth without an initial in-person visit, thanks to a federal DEA waiver extended through December 31, 2026.

But that’s the federal baseline. State laws add layers that can either expand your practice or shut it down entirely. Florida, for example, explicitly prohibits prescribing Schedule II stimulants via telehealth for narcolepsy (it’s only allowed for psychiatric disorders), while New York and California impose no additional state-level barriers beyond federal requirements.

Let’s break down what’s actually happening with the regulations, state by state, and what it means for your practice.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Federal Law: The DEA’s Temporary Telehealth Allowance

The Ryan Haight Act: The Rule That Almost Killed Telehealth Prescribing

Under normal circumstances, the Ryan Haight Online Pharmacy Act (2008) requires at least one in-person medical evaluation before any controlled substance can be prescribed via telemedicine. This law was designed to prevent online ‘pill mills,’ but it created a massive barrier for legitimate telehealth providers treating conditions like narcolepsy, ADHD, and chronic pain.

Pre-COVID, if you wanted to prescribe Adderall for a narcolepsy patient you’d never met in person, you’d be violating federal law — unless you fit into one of the Act’s narrow exceptions (like the patient being seen at a DEA-registered hospital, or being referred by a physician who did conduct an in-person exam).

COVID Changed Everything (Temporarily)

In March 2020, the DEA waived the in-person requirement for the duration of the COVID-19 Public Health Emergency, allowing providers to prescribe Schedule II–V controlled substances via telehealth without ever meeting the patient face-to-face. This was extended multiple times as the pandemic evolved.

Here’s where we are now:

• The Public Health Emergency officially ended May 11, 2023
• DEA has issued four temporary extensions of the telehealth flexibilities since then
• The current extension runs through December 31, 2026 (www.hhs.gov)
• During this window, you can initiate and continue controlled substance prescriptions via video (or in some cases audio) without an in-person visit

What’s Coming: Permanent DEA Rules (Still Pending)

The DEA has been working on permanent telemedicine prescribing regulations since 2022. An initial 2023 proposal suggested requiring an in-person visit after an initial 30-day telemedicine prescription for Schedule II drugs, which drew massive pushback — over 38,000 public comments opposing the restrictions.

As of February 2026, those rules still haven’t been finalized. The DEA has only issued two narrow telemedicine rules (both in January 2025):

1. Allowing buprenorphine prescribing for opioid use disorder via telemedicine without in-person exams
2. Allowing VA patients to continue controlled substance care via telehealth (continuity of care exception)

For narcolepsy specifically, there’s no carve-out yet. You’re operating under the blanket COVID-era extension until broader rules are finalized — which could happen anytime in 2025–2026.

What providers should expect: Final rules will likely allow some form of telehealth prescribing for stimulants (given the pushback to total bans), but may impose conditions like:

• Initial 30-day supply limits with required follow-up
• Documentation requirements proving clinical appropriateness
• Possible registration requirements (DEA floated a ‘Telemedicine Special Registration’ system that hasn’t launched yet)

For now, stay compliant by meeting standard prescribing requirements: proper evaluation (even if via video), PDMP checks, documentation of medical necessity, and following state-specific rules.

State-by-State Breakdown: Where Narcolepsy Telehealth Gets Complicated

California: NP Independence and No Extra Telehealth Barriers

Bottom line: California is one of the most permissive states for both NP practice and telehealth prescribing.

Psychiatrist prescribing: No state restrictions beyond federal law. A California-licensed psychiatrist can diagnose narcolepsy via video, coordinate sleep studies remotely, and prescribe stimulants under the current DEA waiver. Must check the CURES PDMP before initial prescription and at least every 4 months for ongoing therapy.

PMHNP prescribing: California recently phased in full practice authority for NPs via AB 890 (effective 2023). Experienced NPs (≥4,600 hours or 3 years supervised practice) can become ‘104 NPs’ who practice independently without physician oversight. They can prescribe Schedule II–V medications, including stimulants for narcolepsy, after completing required pharmacology training on controlled substances.

What this means practically: A PMHNP with California’s independent certification can run a narcolepsy telemedicine practice solo — diagnose, prescribe Adderall or modafinil, manage ongoing care — without a supervising physician. They need a DEA registration, BRN Schedule II furnishing certification, and to follow PDMP requirements.

Telehealth specifics: No state-mandated in-person visit. Standard of care still applies — document thorough exams via video, coordinate any needed in-person diagnostics (like sleep studies), and maintain appropriate follow-up.

Texas: Strict NP Limits and Video-Only Prescribing

Bottom line: Texas allows telehealth prescribing for psychiatrists but has some of the strictest NP scope restrictions in the country.

Psychiatrist prescribing: Telehealth is permitted via two-way video (audio-only doesn’t meet Texas requirements for controlled substance prescribing). No state-imposed in-person requirement beyond federal law. Must check Texas PMP before prescribing.

Texas does ban telehealth prescribing for chronic pain management with controlled substances (requiring regular in-person visits), but narcolepsy isn’t classified as chronic pain, so this doesn’t apply to stimulant prescribing for excessive daytime sleepiness.

PMHNP prescribing: This is where Texas gets restrictive. APRNs cannot prescribe Schedule II controlled substances in outpatient settings. The only exceptions are:

• Inpatient hospital admissions (≥24 hours)
• Emergency department care
• Hospice patients (filled at hospice pharmacy)

An outpatient narcolepsy patient? Your PMHNP cannot write the Adderall prescription. Period. The supervising physician must write Schedule II prescriptions (www.tmb.state.tx.us).

PMHNPs can prescribe Schedule III–IV medications under delegation, so modafinil (Schedule IV) is an option. But for traditional stimulants, you need physician involvement.

Practice model implications: Telehealth platforms operating in Texas typically structure services with psychiatrists handling Schedule II prescriptions, or use hybrid models where NPs manage initial evaluations and non-stimulant therapy, with MD sign-off for stimulants.

Florida: The Telehealth Ban on Narcolepsy Stimulants

Bottom line: Florida has a specific state law prohibiting Schedule II stimulant prescribing via telehealth for narcolepsy. This is the biggest regulatory barrier in our six-state analysis.

The law: Florida Statute §456.47 states that providers cannot prescribe Schedule II or III controlled substances via telehealth except for:

• Psychiatric disorders
• Inpatient hospital care
• Hospice patients
• Nursing home residents

Narcolepsy is a neurological sleep disorder, not a psychiatric disorder, so it doesn’t qualify for the psychiatric exception. A Florida provider cannot legally prescribe Adderall or methylphenidate for narcolepsy via telehealth alone (www.leg.state.fl.us).

Workarounds:

1. Use Schedule IV alternatives: Modafinil and armodafinil (Schedule IV) can be prescribed via telehealth in Florida since the ban only covers Schedule II and III
2. Require one in-person visit: Some providers do an initial in-person evaluation (or partner with a local clinic) to establish the patient and initiate stimulants, then continue follow-up care via telehealth
3. Coordinate with sleep specialists: Refer to a local sleep medicine physician for the in-person diagnostic workup and initial prescription, then manage ongoing psychiatric comorbidities remotely

PMHNP prescribing in Florida: Even if you solve the telehealth issue, Florida limits NP Schedule II prescribing to 7-day supplies unless the NP is a certified ‘psychiatric nurse’ treating a mental health disorder (www.flsenate.gov). Since narcolepsy isn’t a psychiatric diagnosis, the 7-day limit would apply — making long-term management by an NP impractical without physician involvement.

Reality check: Florida is a tough state for narcolepsy telehealth. Most platforms either don’t offer stimulant prescribing for narcolepsy in FL, focus on modafinil-based treatment, or require hybrid in-person/telehealth models.

New York: Federal Alignment with State Oversight

Bottom line: New York explicitly aligned its state controlled substance rules with federal telehealth policy in 2025, creating a clear framework.

The rule: NY regulations require an in-person exam before prescribing controlled substances unless specific exceptions apply. The key exception: prescribing is done in accordance with applicable federal law (www.nixonpeabody.com).

Since federal law (via DEA waiver) currently allows telehealth prescribing through 2026, New York providers can prescribe narcolepsy stimulants via telehealth right now. If/when federal law changes to require in-person exams, New York’s requirement automatically kicks in — unless you qualify for another state exception (like the patient being recently seen by a referring provider, or you’re covering for another prescriber).

PMHNP scope: New York has full practice authority for experienced NPs (≥3,600 hours). Independent NPs can diagnose and manage narcolepsy without physician oversight, including prescribing Schedule II–V medications. They need:

• NYS Education Department prescriptive authority certificate
• DEA registration
• Registration with I-STOP (NY’s prescription monitoring program)
• E-prescribing capability (mandatory in NY)

Practical considerations: New York’s I-STOP database must be checked before every controlled substance prescription. The state takes PDMP compliance seriously — violations can result in license discipline.

Pennsylvania: Collaboration Required, Telehealth Permitted

Bottom line: Pennsylvania is a restricted practice state for NPs but doesn’t impose extra telehealth barriers beyond federal requirements.

Psychiatrist prescribing: No state prohibition on telehealth controlled substance prescribing. Must follow standard of care for remote evaluations and check Pennsylvania PMP before prescribing. A proper video exam is expected.

Pennsylvania passed Act 69 (2021) officially recognizing telehealth practice standards, but deferred to federal law on controlled substance specifics. The state does allow telehealth initiation of buprenorphine for opioid treatment with in-person follow-up within 14 days (www.cchpca.org) — suggesting openness to telehealth prescribing with appropriate safeguards.

PMHNP prescribing: CRNPs must have a collaborative agreement with a physician. For Schedule II prescriptions, there’s a 30-day supply limit initially, with physician consultation required for ongoing therapy (Pennsylvania removed the old 72-hour initial limit in 2021 regulations). Schedule III–IV medications have a 90-day supply limit.

For narcolepsy, this means:

• A Pennsylvania PMHNP can prescribe an initial 30-day supply of Adderall via telehealth (under collaboration and current DEA rules)
• The supervising physician must be consulted for continued prescribing beyond that
• Modafinil (Schedule IV) can be prescribed for up to 90 days under the collaborative agreement

Practice structure: The collaborative agreement must specify which controlled substances the NP is authorized to prescribe. Narcolepsy medications should be explicitly listed. There’s no limit on the number of NPs a physician can supervise in PA (that restriction was removed), which helps scalability.

Illinois: Full Practice Authority (With Experience)

Bottom line: Illinois allows independent NP practice after meeting experience requirements, with no extra state-level telehealth barriers.

PMHNP scope: Illinois law (Public Act 100-0187, effective 2017) grants Full Practice Authority to NPs who complete:

• Minimum 4,000 hours of practice under a collaborative agreement
• 250 hours of additional continuing education in their specialty

Once granted FPA, Illinois NPs can prescribe Schedule II–V controlled substances independently. They must obtain an Illinois Mid-Level Practitioner Controlled Substance License in addition to their DEA registration.

The catch: Illinois law requires a ‘consultation relationship’ with a physician if an FPA-NP prescribes benzodiazepines or opioids. Stimulants aren’t explicitly mentioned in this requirement, so it likely doesn’t apply to narcolepsy prescribing — but the statute’s wording is somewhat ambiguous. Conservative interpretation: maintain a consultation relationship for any high-risk controlled substance prescribing.

Telehealth specifics: No state prohibition on telehealth controlled substance prescribing. Must check Illinois PMP before prescribing. E-prescribing is mandatory for all controlled substances as of January 2023 (with limited exceptions).

What this means: An experienced PMHNP in Illinois can run an independent narcolepsy telemedicine practice, prescribing stimulants and managing ongoing care, with minimal physician involvement (beyond maintaining a consultation relationship for documentation purposes).

Comparing State Rules: Quick Reference Table

The Narcolepsy-Specific Challenge: Diagnosis Requirements

Here’s a reality check about treating narcolepsy via telehealth that goes beyond prescribing authority: confirming a narcolepsy diagnosis requires testing that can’t be done remotely.

Standard diagnostic workup includes:

• Overnight polysomnography (sleep study) to rule out other sleep disorders
• Multiple Sleep Latency Test (MSLT) to measure daytime sleepiness and detect REM sleep abnormalities characteristic of narcolepsy

These require in-person sleep lab visits. A purely virtual provider can’t skip this step and maintain standard of care.

How telehealth narcolepsy practices handle this:

1. Coordinate with local sleep centers: Refer patients for diagnostic testing in their area, review results remotely, then initiate treatment via telehealth once diagnosis is confirmed
2. Manage established patients: Focus on patients who already have confirmed narcolepsy diagnoses and need ongoing medication management
3. Hybrid models: Partner with brick-and-mortar clinics or sleep specialists who handle the diagnostic workup, then provide remote follow-up care

You can’t diagnose narcolepsy on video alone. But you can manage it remotely once the diagnosis is established — and that’s where telehealth adds significant value, especially in underserved areas with few sleep specialists or psychiatrists.

Practical Compliance: What Providers Actually Need to Do

Whether you’re joining a telehealth platform or launching your own practice, here’s what compliance looks like in 2026:

Before Prescribing

Every state, every time:

• Check the state PDMP (prescription drug monitoring program) before initial prescription and periodically for ongoing therapy

• California: CURES (at least every 4 months)

• Texas: Texas PMP (every prescription)

• Florida: E-FORCSE (mandatory check)

• New York: I-STOP (every prescription)

• Pennsylvania: PA PMP (each prescription)

• Illinois: Illinois PMP (before prescribing opioids and ‘designated controlled substances’ which include stimulants)

• Use e-prescribing (most states mandate it for controlled substances)

• Document the clinical encounter as thoroughly as an in-person visit

• Verify patient identity and location (required for proper licensing compliance)

The Video Exam Standard

Even though no in-person visit is required federally (through 2026), you must conduct a clinically appropriate evaluation via telehealth. For narcolepsy, that includes:

• Detailed sleep history (excessive daytime sleepiness, cataplexy, sleep paralysis, hypnagogic hallucinations)
• Review of prior sleep studies (polysomnography, MSLT results)
• Mental status exam (psychiatric comorbidities are common)
• Medication history and prior treatment responses
• Assessment of abuse risk (stimulants have diversion potential)
• Use of validated scales (Epworth Sleepiness Scale, etc.)

What you can observe on video:

• General appearance and alertness
• Obvious sleepiness during the visit
• Speech patterns
• Mental status elements (orientation, memory, attention)
• Medication pill counts (ask patient to show bottles)

What you can’t observe: Physical exam findings requiring hands-on assessment. For narcolepsy specifically, the neurological exam is usually normal, so this is less of a barrier than for other conditions. But document what you can assess and coordinate in-person evaluations when clinically indicated.

Risk Management: CYA Documentation

Given the uncertain regulatory future, document defensively:

• Why telehealth is appropriate for this patient (access barriers, established diagnosis, stable condition)
• How you established medical necessity for controlled substances
• Your rationale for the specific medication and dose
• Follow-up plan and frequency
• Red flags you screened for (substance use history, diversion risk, concurrent controlled substances from other providers)

If the DEA rules change or you’re ever audited, you want clear evidence that each prescription was for a ‘legitimate medical purpose in the usual course of professional practice’ — the standard required by federal controlled substance law.

What Happens When the DEA Waiver Ends?

Scenario 1: DEA requires in-person exams for Schedule II initiation

You’ll need to either:

• Require new narcolepsy patients to have at least one in-person visit (with you or a partnered provider) before starting stimulants
• Use modafinil or other Schedule IV alternatives for initial telehealth treatment
• Only accept established patients who were already seen in person pre-waiver

Scenario 2: DEA allows limited telehealth prescribing (e.g., 30-day initial supply)

You could initiate treatment remotely with a short supply, then either:

• Arrange an in-person follow-up within 30 days for ongoing prescriptions
• Transition to a hybrid model (telehealth + periodic in-person visits)

Scenario 3: DEA creates a special telemedicine registration

You’d need to complete whatever registration process DEA implements (likely additional training, documentation requirements, or practice standards) to continue teleprescribing controlled substances.

The smart move: Build relationships with local providers now (sleep specialists, primary care, other psychiatrists) who can handle in-person components if regulations tighten. Don’t build a practice model that completely collapses if the waiver ends.

Economics: Why Narcolepsy Telehealth Makes Sense (Despite the Complexity)

Narcolepsy is rare (affects ~1 in 2,000 people) and chronically underdiagnosed. Most communities don’t have local sleep specialists, and psychiatric providers who understand narcolepsy management are even scarcer.

Patient acquisition reality:

• Patients with confirmed narcolepsy diagnoses actively seek specialists
• Word-of-mouth and online reviews drive referrals in rare disease communities
• Insurance typically covers telehealth psychiatry at the same rate as in-person (thanks to recent parity laws)
• Cash-pay narcolepsy patients exist but are less common (medications are expensive without insurance)

The platform advantage:

Instead of spending months building SEO, running Google Ads at $15-40+ per click, and paying for directory listings that get you lost among hundreds of other providers, a platform like Klarity Health delivers:

• Pre-qualified patients already matched to your specialty and availability
• No upfront marketing spend — you only pay when a patient books with you (pay-per-appointment model)
• Built-in telehealth infrastructure (no separate EHR/video platform costs)
• Both insurance and cash-pay patient flow without you managing billing
• You control your schedule — scale up or down based on your availability

The economics work because:

• Narcolepsy patients need ongoing care (monthly follow-ups for medication management) = recurring revenue, not one-time visits
• The complexity of regulations means fewer providers are willing to handle it = less competition for specialized services
• Telehealth removes geographic barriers = larger patient pool from underserved areas

DIY marketing for a niche specialty like narcolepsy can easily cost $3,000-5,000/month with uncertain results (SEO takes 6-12 months, Google Ads conversion rates are poor for medical keywords, directory fees add up with minimal differentiation). A pay-per-appointment model removes that risk entirely — you pay only when you see qualified patients, not for clicks that don’t convert or monthly subscriptions with no guarantee of patient volume.

FAQ: What Providers Actually Ask

Can I prescribe Adderall for narcolepsy via telehealth right now?

It depends on your state. Under federal law (DEA waiver through 12/31/2026), yes. But Florida state law prohibits it. Texas, California, New York, Pennsylvania, and Illinois all permit it under current federal rules. Always verify your specific state’s current regulations.

What if I’m licensed in multiple states through the Interstate Medical Licensure Compact (IMLC)?

The IMLC speeds up obtaining licenses in member states (Texas, Pennsylvania, and Illinois are members; California, New York, and Florida are not). You still must comply with each state’s prescribing rules individually. A Texas license doesn’t exempt you from Texas’s APRN Schedule II restrictions, and a Pennsylvania license doesn’t override Florida’s telehealth ban.

Do I need a separate DEA registration for each state?

No. As of recent DEA policy, you get one DEA number that covers all states where you’re licensed, but you must list a physical practice address in each state. When you add a new state license, update your DEA registration to include that state’s address.

Can PMHNPs diagnose narcolepsy, or is that outside our scope?

Legally, yes — in states where NPs have appropriate autonomy (California, New York, Illinois), there’s no law prohibiting a PMHNP from diagnosing narcolepsy. Practically, it depends on your training and competency. Narcolepsy is a neurological sleep disorder, not a primary psychiatric condition. If you don’t have specific training in sleep medicine, the standard of care likely requires coordinating with or referring to a sleep specialist for diagnosis confirmation (via sleep studies) and complex cases. You can absolutely manage the medications once diagnosed, especially since many narcolepsy drugs overlap with psychiatric prescribing (stimulants, antidepressants for cataplexy).

What about sodium oxybate (Xyrem) for narcolepsy with cataplexy?

Sodium oxybate is Schedule III with an FDA-mandated REMS program. To prescribe it, you must enroll in the REMS system, and patients must enroll before receiving the medication. It’s dispensed through a single central pharmacy with strict distribution controls. Telehealth prescribing is allowed under current federal rules (it’s Schedule III, not II, so even Florida’s ban doesn’t apply). The REMS enrollment adds administrative overhead but is doable via telehealth platforms that support specialty pharmacy coordination.

How do I arrange sleep studies for telehealth patients?

Coordinate with local sleep centers in the patient’s area. Most accept referrals from out-of-state providers (especially if you’re licensed in that state). The patient goes to the local lab for overnight polysomnography and MSLT, results are sent to you electronically, and you review them during a follow-up telehealth visit to confirm diagnosis and initiate treatment. Some home sleep apnea tests exist, but they’re not adequate for diagnosing narcolepsy (which requires in-lab MSLT).

What happens to my existing narcolepsy patients if the DEA waiver ends?

Established patients are usually grandfathered under most proposed rules. The Ryan Haight Act already has exceptions for ‘covering practitioners’ who prescribe to established patients of another provider. If you’ve been treating a patient via telehealth for months under the waiver, you’d likely qualify to continue prescribing even if new patients require in-person exams. But document that prior relationship thoroughly.

The Bottom Line: Positioning Yourself for 2026 and Beyond

The regulatory landscape for narcolepsy telehealth is complex, state-dependent, and guaranteed to change sometime in the next 12 months when permanent DEA rules drop.

If you’re a psychiatrist:

• You have the clearest path to treating narcolepsy remotely in most states
• Focus on building competency in sleep disorder management (even basic training puts you ahead of most general psychiatrists)
• Get licensed in multiple states to expand your patient base, prioritizing states with favorable rules (California, New York, Illinois) or high unmet need (Texas, despite restrictions)
• Prepare for potential in-person visit requirements by establishing referral relationships with local providers now

If you’re a PMHNP:

• Your scope depends entirely on your state — maximize it where you can (CA, NY, IL) and work within collaborative structures where required (PA, TX)
• In restricted states like Texas and Florida, focus on Schedule III-IV medications (modafinil) or position yourself as part of a care team with physician oversight for stimulants
• Consider relocating your practice to a full practice authority state if narcolepsy/complex prescribing is your focus
• Document your training and competency in sleep disorders proactively (continuing education, case logs) to demonstrate appropriateness of your scope

For both:

The smart play is joining a platform that handles the regulatory complexity, patient acquisition, and infrastructure while you focus on clinical care. Klarity Health’s pay-per-appointment model removes the risk of upfront marketing investment and gives you immediate access to patients who need specialized care — without spending months building your own telehealth practice from scratch.

Narcolepsy patients are underserved, actively seeking providers, and need ongoing management. The regulations are navigable if you understand them. And the opportunity to expand access to quality care while building a sustainable practice is real.

Just make sure you’re complying with your state’s specific rules — because ‘telehealth is allowed’ at the federal level doesn’t mean it’s allowed everywhere.

References and Citations

1. HHS Press Release – ‘HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026’ (January 2, 2026). U.S. Department of Health & Human Services. www.hhs.gov

2. DEA Press Release – ‘DEA and HHS Extend Telemedicine Flexibilities through 2025’ (November 15, 2024). U.S. Drug Enforcement Administration. www.dea.gov

3. 21 U.S.C. §829(e) – Ryan Haight Act statutory definitions (in-person medical evaluation requirement). Legal Information Institute, Cornell Law School. www.law.cornell.edu

4. Florida Statutes §456.47 – Use of Telehealth to Provide Services (controlled substance prescribing restrictions). Florida Legislature Online Sunshine. www.leg.state.fl.us

5. Nixon Peabody Legal Alert – ‘New York State Finalizes Telemedicine Rule for Controlled Substances’ (June 18, 2025). Healthcare law analysis of NYSDOH final rule effective May 2025. www.nixonpeabody.com

Source:

• https://www.law.cornell.edu/definitions/uscode.php?defid=21-USC-1796173870-113781527&height=800&iframe=true&termoccur=999&term_src=title%3A21%3Achapter%3A13%3Asubchapter%3AI%3Apart%3AC%3Asection%3A831&width=840#:~:text=,that%20a%20prescription%20has%20been
• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,while%20permanent%20rules%20are%20finalized
• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=promulgate%20a%20final%20set%20of,Medications%2C%E2%80%9D%20was%20submitted%20to%20the
• https://www.dea.gov/press-releases/2025/12/31/dea-extends-telemedicine-flexibilities-ensure-continued-access-care#:~:text=On%20January%2017%2C%202025%2C%20DEA,to%20as%20the%20%E2%80%9CTwo%20Final
• https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499%2F0456%2FSections%2F0456.47.html#:~:text=telehealth%20to%20provide%20health%20care,in%20Schedule%20II%20of%20s
• https://www.tmb.state.tx.us/page/facility-based-prescriptive-delegation#:~:text=at%20the%20hospital%E2%80%99s%20facility,from%20a%20qualified%20hospice%20provider
• https://www.cchpca.org/resources/state-telehealth-laws-and-reimbursement-policies-report-fall-2025/#:~:text=Texas%20regulations%20emphasize%20continuity%20of,Note
• https://www.nixonpeabody.com/insights/alerts/2025/06/18/new-york-state-finalizes-telemedicine-rule-for-controlled-substances#:~:text=match%20at%20L114%20The%20rule,and%20the%20US%20Department%20of
• https://www.nixonpeabody.com/insights/alerts/2025/06/18/new-york-state-finalizes-telemedicine-rule-for-controlled-substances#:~:text=In%20short%2C%20the%20exception%20permits,as%20a%20condition%20of%20state
• https://rxagent.co/blog/np-prescribing-authority#:~:text=Conversely%2C%20in%20Restricted%20Practice%20states,expand%20this%20scope%20%206